论文部分内容阅读
国家食品药品监管总局发布药品不良反应信息通报,提示关注注射用头孢硫脒存在的过敏性休克、呼吸困难等不良反应及儿童用药风险。注射用头孢硫脒是我国自主研发的全身抗感染药,适应症用于敏感菌所引起的呼吸系统、肝胆系统、五官、尿路感染及心内膜炎、败血症。通报显示,自2014年7月1日至2015年6月30日,国家药品不良反应监测数据库中收到注射用头孢硫脒致不良反应/事件报告5802例,严重不良反应/事件报告277例,主要表现为过敏性休克、过敏样反应、呼吸困难、心悸、胸闷等。儿童报告较多,其中6岁以下儿童注射用头孢硫脒不
State Food and Drug Administration issued a drug adverse reaction information bulletin reminding the injection of cefathiamidine presence of anaphylactic shock, dyspnea and other adverse reactions and children medication risk. Cefathiamidine for injection is a self-developed systemic anti-infective drug developed in China. Indications are used in the respiratory system, hepatobiliary system, facial features, urinary tract infections and endocarditis and septicemia caused by sensitive bacteria. The circular shows that from July 1, 2014 to June 30, 2015, 5802 cases of adverse reactions / incidents of cefathioxime were reported and 277 cases of serious adverse reactions / incidents were reported in the national ADR monitoring database. The main manifestations of anaphylactic shock, allergic reactions, dyspnea, heart palpitations, chest tightness and so on. Children reported more, of which children under 6 years of age cefathiamidine injection is not